FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034881138> ?p ?o ?g. }

• W2034881138 endingPage "931" @default.
• W2034881138 startingPage "931" @default.
• W2034881138 abstract "Abstract Constitutively activated pY705-STAT3 is oncogenic and prevalent in many tumor types, and has been shown to be driven in large part by constitutive autocrine and paracrine cytokine signaling. JAK kinases are critical mediators of cytokine signaling, and JAK1 has been shown to play an essential role downstream of IL-6 family cytokines, the upregulation of which has been documented in many tumor types. A JAK1 selective inhibitor should provide a therapeutic means of suppressing Y705 phosphorylation of STAT3 without incurring the hematological toxicity associated with inhibition of JAK2 and JAK3 activity, allowing for more intensive dosing and greater combinability with other agents, particularly those with hematological toxicities. We have developed highly selective inhibitors of JAK1 and used them to address the hypothesis that JAK1 is the primary driver of STAT3 mediated signaling in cancer cells. The compounds are highly selective in enzyme assays, with 1000-fold selectivity for JAK1 vs. other JAK family members, and minimal activity against other kinases at 1uM. In cell lines, they are over 500-fold selective for JAK1 vs. JAK2, measured using assays specific for JAK1-mediated STAT3 vs. JAK2-mediated STAT5 phosphorylation. In vivo, the compounds are also highly selective for JAK1 mediated signaling, measured by comparing inhibition of STAT3 phosphorylation in H1975 subcutaneous xenografts vs. inhibition of STAT5 phosphorylation in a disseminated TEL-JAK2 transformed BaF3 model. At doses where inhibition of STAT3 phosphorylation was greater than 90%, only minimal inhibition of STAT5 phosphorylation was observed. In a wide variety of human tumor lines (CRC, NSCLC, pancreatic, DLBCL) with a variety of genetic backgrounds (K-ras, b-raf, PI3K, EGFR mutant, PTEN null), complete knockdown of pSTAT3 (Y705) was observed with JAK1 selective compounds, at concentrations achievable in vivo. These effects are consistent with experiments where inhibition of Y705 phosphorylation of STAT3 was achieved with a JAK1-specific siRNA. At doses where in vivo activity was observed, the compounds had only minimal effect in an erythropoietin-driven mouse model of polycythemia and extramedullary erythropoiesis. These data support the hypotheses that in a variety of tumor types, pSTAT3-mediated signaling is dependent on JAK1 kinase activity, and that a selective JAK1 inhibitor can suppress STAT3 activation at doses that avoid the hematological toxicity associated with JAK2 and JAK3 inhibition. Citation Format: Richard Woessner, Geraldine Bebernitz, Kirsten Bell, Robert Caccese, Nakpangi Johnson, Jason Kettle, Caroline Rivard, Patricia Schroeder, Qibin Su, Haixia Wang, Minwei Ye, Weijia Zheng, Michael Zinda, Paul Lyne, Melissa Vasbinder, Dennis Huszar, Claudio Chuaqui. Highly selective JAK1 kinase inhibitors suppress Y705-mediated STAT3 activation in a wide range of tumor types, with reduced hematological toxicity. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 931. doi:10.1158/1538-7445.AM2013-931" @default.
• W2034881138 created "2016-06-24" @default.
• W2034881138 creator A5001064231 @default.
• W2034881138 creator A5010293166 @default.
• W2034881138 creator A5013946717 @default.
• W2034881138 creator A5016791761 @default.
• W2034881138 creator A5025568649 @default.
• W2034881138 creator A5030065450 @default.
• W2034881138 creator A5033169967 @default.
• W2034881138 creator A5042406680 @default.
• W2034881138 creator A5044437841 @default.
• W2034881138 creator A5048516275 @default.
• W2034881138 creator A5054565788 @default.
• W2034881138 creator A5059472140 @default.
• W2034881138 creator A5067040049 @default.
• W2034881138 creator A5075510757 @default.
• W2034881138 creator A5078391610 @default.
• W2034881138 creator A5085715461 @default.
• W2034881138 creator A5087791639 @default.
• W2034881138 date "2013-04-01" @default.
• W2034881138 modified "2023-10-17" @default.
• W2034881138 title "Abstract 931: Highly selective JAK1 kinase inhibitors suppress Y705-mediated STAT3 activation in a wide range of tumor types, with reduced hematological toxicity." @default.
• W2034881138 doi "https://doi.org/10.1158/1538-7445.am2013-931" @default.
• W2034881138 hasPublicationYear "2013" @default.
• W2034881138 type Work @default.
• W2034881138 sameAs 2034881138 @default.
• W2034881138 citedByCount "2" @default.
• W2034881138 countsByYear W20348811382018 @default.
• W2034881138 countsByYear W20348811382019 @default.
• W2034881138 crossrefType "journal-article" @default.
• W2034881138 hasAuthorship W2034881138A5001064231 @default.
• W2034881138 hasAuthorship W2034881138A5010293166 @default.
• W2034881138 hasAuthorship W2034881138A5013946717 @default.
• W2034881138 hasAuthorship W2034881138A5016791761 @default.
• W2034881138 hasAuthorship W2034881138A5025568649 @default.
• W2034881138 hasAuthorship W2034881138A5030065450 @default.
• W2034881138 hasAuthorship W2034881138A5033169967 @default.
• W2034881138 hasAuthorship W2034881138A5042406680 @default.
• W2034881138 hasAuthorship W2034881138A5044437841 @default.
• W2034881138 hasAuthorship W2034881138A5048516275 @default.
• W2034881138 hasAuthorship W2034881138A5054565788 @default.
• W2034881138 hasAuthorship W2034881138A5059472140 @default.
• W2034881138 hasAuthorship W2034881138A5067040049 @default.
• W2034881138 hasAuthorship W2034881138A5075510757 @default.
• W2034881138 hasAuthorship W2034881138A5078391610 @default.
• W2034881138 hasAuthorship W2034881138A5085715461 @default.
• W2034881138 hasAuthorship W2034881138A5087791639 @default.
• W2034881138 hasConcept C11960822 @default.
• W2034881138 hasConcept C128240485 @default.
• W2034881138 hasConcept C170493617 @default.
• W2034881138 hasConcept C184235292 @default.
• W2034881138 hasConcept C185592680 @default.
• W2034881138 hasConcept C203014093 @default.
• W2034881138 hasConcept C2778690821 @default.
• W2034881138 hasConcept C2778923194 @default.
• W2034881138 hasConcept C2779391668 @default.
• W2034881138 hasConcept C32465701 @default.
• W2034881138 hasConcept C502942594 @default.
• W2034881138 hasConcept C55493867 @default.
• W2034881138 hasConcept C62478195 @default.
• W2034881138 hasConcept C7876069 @default.
• W2034881138 hasConcept C86803240 @default.
• W2034881138 hasConcept C98274493 @default.
• W2034881138 hasConceptScore W2034881138C11960822 @default.
• W2034881138 hasConceptScore W2034881138C128240485 @default.
• W2034881138 hasConceptScore W2034881138C170493617 @default.
• W2034881138 hasConceptScore W2034881138C184235292 @default.
• W2034881138 hasConceptScore W2034881138C185592680 @default.
• W2034881138 hasConceptScore W2034881138C203014093 @default.
• W2034881138 hasConceptScore W2034881138C2778690821 @default.
• W2034881138 hasConceptScore W2034881138C2778923194 @default.
• W2034881138 hasConceptScore W2034881138C2779391668 @default.
• W2034881138 hasConceptScore W2034881138C32465701 @default.
• W2034881138 hasConceptScore W2034881138C502942594 @default.
• W2034881138 hasConceptScore W2034881138C55493867 @default.
• W2034881138 hasConceptScore W2034881138C62478195 @default.
• W2034881138 hasConceptScore W2034881138C7876069 @default.
• W2034881138 hasConceptScore W2034881138C86803240 @default.
• W2034881138 hasConceptScore W2034881138C98274493 @default.
• W2034881138 hasIssue "8_Supplement" @default.
• W2034881138 hasLocation W20348811381 @default.
• W2034881138 hasOpenAccess W2034881138 @default.
• W2034881138 hasPrimaryLocation W20348811381 @default.
• W2034881138 hasRelatedWork W1547412330 @default.
• W2034881138 hasRelatedWork W1968968766 @default.
• W2034881138 hasRelatedWork W1975063481 @default.
• W2034881138 hasRelatedWork W2009085380 @default.
• W2034881138 hasRelatedWork W2016852812 @default.
• W2034881138 hasRelatedWork W2020348993 @default.
• W2034881138 hasRelatedWork W2034881138 @default.
• W2034881138 hasRelatedWork W2053060921 @default.
• W2034881138 hasRelatedWork W2099792017 @default.
• W2034881138 hasRelatedWork W4235419707 @default.
• W2034881138 hasVolume "73" @default.
• W2034881138 isParatext "false" @default.
• W2034881138 isRetracted "false" @default.
• W2034881138 magId "2034881138" @default.
• W2034881138 workType "article" @default.